Case Based Roundtable Logo

This roundtable series assesses the use of immunotherapies in combination for patients with renal cell carcinoma, as discussed by key opinion leaders and participants at virtual live events.

Using Immunotherapy Combinations in Multiple Lines of RCC Treatment

Patient Considerations for Using Dual Immunotherapy for RCC
Patient Considerations for Using Dual Immunotherapy for RCC
June 26, 2024
During a Case-Based Roundtable® event, Nizar M. Tannir, MD, discussed the importance of site of metastasis and other factors in the use of nivolumab plus ipilimumab in renal cell carcinoma in the first article of a 2-part series.
Key Takeaways From QOL and Use of Steroids With IO-Based RCC Regimens
Key Takeaways From QOL and Use of Steroids With IO-Based RCC Regimens
May 06, 2024
During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Long-Term Ipi/Nivo RCC Data Show Durability Across Risk Groups
Long-Term Ipi/Nivo RCC Data Show Durability Across Risk Groups
April 12, 2024
During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the 8-year follow-up data of ipilimumab plus nivolumab in patients with advanced renal cell carcinoma In the first article of a 2-part series.
Unique Challenges of Using IO/TKI Combinations in Metastatic RCC
Unique Challenges of Using IO/TKI Combinations in Metastatic RCC
March 12, 2024
During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, asked participants to share their experiences using nivolumab plus cabozantinib in patients with advanced renal cell carcinoma. This is the second of 2 articles based on this event.
Risk Groups Vital to Interpreting Results of RCC Immunotherapy Trials
Risk Groups Vital to Interpreting Results of RCC Immunotherapy Trials
February 21, 2024
During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, examined the impact of the CheckMate 214 and CheckMate 9ER trials of nivolumab/ipilimumab and nivolumab/cabozantinib in patients with advanced renal cell carcinoma. This is the first of 2 articles based on this event.